Navigation Links
CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Date:1/16/2008

- Tyrima Exhibits Excellent Safety Profile and Favorable Pharmacokinetics

in Phase I Studies -

RESEARCH TRIANGLE PARK, N.C., Jan. 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced the successful completion of the Phase l clinical program for Tyrima(TM), its lead candidate for the treatment of depression and anxiety. Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A. The Phase l program included acute dose, repeat dose and fed-fasted studies. The results of all studies were favorable, showing that Tyrima was safe and well tolerated and exhibited good pharmacokinetic properties.

"Tyrima has the potential to be the first triple-action antidepressant capable of treating a broad patient population, and we are very pleased with the safety and tolerability observed in the Phase l clinical program," said Dr. Daniel Burch, R&D head and chief medical officer of CeNeRx. "Monoamine oxidase A inhibitors (MAOI) have demonstrated efficacy advantages over conventional antidepressants, but their use has been limited by their potential for serious adverse food effects. In these Phase l studies, Tyrima demonstrated good safety and excellent drug-like properties, with a positive pharmacokinetic profile at all doses tested and minimal signs of fed-fasted effects. We look forward to initiating the Phase ll program in the second quarter of 2008."

Like conventional MAOI agents, the triple-action mechanism of Tyrima elevates the levels of three key neurotransmitters (serotonin, norepinephrine and dopamine) that positively affect mood and anxiety. In contrast, most of the current leading antidepressant drugs affect only the single neurotransmitter serotonin. However, unlike older MAOIs, the unique selectivity and reversibility
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
2. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
5. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
6. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
10. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... HILDEN , Germany and ... -- , Collaboration aims to ... plasma samples to guide the use of IRESSA  for ... test will build on QIAGEN,s FDA-approved  therascreen   EGFR test ... QIAsymphony family of automated instruments  Project enabled ...
(Date:7/25/2014)... HILL, N.C. , July 25, 2014  Corporate ... challenges, including understanding new advancements in technology and how ... of this, libraries in the pharmaceutical and medical device ... value of the information and services they provide. ... Best Practices, LLC there are many forces of change ...
(Date:7/25/2014)... 2014  Smile Train and its technology partner BioDigital ... Surgery Simulator among leading global health innovations in The ... Washington, D.C. at The John ... "Smile Train is honored to be represented through ... innovators in health and medicine that TEDMED unites each ...
Breaking Medicine Technology:QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Forces of Change Reshaping Corporate Libraries & Information Services 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3
... , ATLANTA, Dec. 23 MiMedx Group, Inc. ... launched its first product, Paradis Vaso Shield(TM). In April ... for use as a cover for vessels following anterior vertebral ... hydrogel product protected by multiple patents and patent applications, as ...
... FRANCISCO, Dec. 23 Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing ... that management will present at the following upcoming investor conferences. , ... January 12, 2010, 9:40 a.m. PT, ... OneMedForum 2010, Wednesday, January 13, 2010, ...
Cached Medicine Technology:MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 3
(Date:7/28/2014)... St. Jude Children’s Research Hospital ... of Defense Employer Support Freedom Award from the Employer Support ... Defense. The award is the highest honor given by the ... who serve in the National Guard and Reserve. , “We ... their contributions to the St. Jude mission and to our ...
(Date:7/28/2014)... possible by a test developed at University of Colorado ... of Pharmacy), AURORA, Colo (July 28, 2014) An influential ... Pharmacology Laboratory at the CU School of Pharmacy, helps ... Truvada (a combination of tenofovir/emtricitabine), which is taken once ... presented during the AIDS 2014 Conference and published in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... Lipase), Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, ... Forecasts to 2018” defines and segments the global ... the global value for industrial enzymes. It also ... industrial enzymes market with analysis of trends, opportunities, ...
(Date:7/28/2014)... 2014 Qualis Health, one of ... organizations, has published a complimentary, online toolkit that ... patients and families in infection control. Tested ... the toolkit provides a step-by-step roadmap for implementing ... their families early in a hospital stay. , ...
(Date:7/28/2014)... Dennis Thompson HealthDay ... -- Babies born prematurely appear to have a slightly ... will carry into adulthood, Swedish researchers report. Doctors ... weeks, gestation have a raised risk of deep vein ... blood clotting in the veins, the researchers noted in ...
Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3
... Colonic lipomas have been found in related literature. One ... 14 issue of the World Journal of Gastroenterology because ... discussed age and sex factors, clinical and histopathological findings, ... and previously available literature. , The article reported ...
... Food and Drug Administration (FDA) has awarded the ... $1 million Orphan Products Development grant to study ... skin or internal organs., The unique, interdisciplinary, and ... Drolet, M.D., professor of dermatology and pediatrics, at ...
... Researchers at the Board of Governors Gene Therapeutics Research ... first time that it is possible to sustain therapeutic ... to a year, even in the presence of an ... humans. , The researchers demonstrated in an animal ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... long-term outcomes, researchers say , THURSDAY, Oct. 25 (HealthDay News) ... peptide (ANP) can lessen cardiac injuries after heart attack and ... a Japanese study in this week,s issue of The ... damaged heart muscle (infarct) and lessened what,s known as "reperfusion ...
... 26 AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Inc Webcast, When: November 1, 2007 @ 8:30 AM ... over the Internet -- Simply log on to the web at ... Contact: Lisa Gould of AMICAS, Inc, 617-779-7892. If you ...
Cached Medicine News:Health News:The largest colonic lipoma to date 2Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2
1000 L, Racked, Pre-sterilized, 100 tips/rack Recommended for 500 and 1000 L pipettes....
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
... ideal for PCR and other ... work where aerosol contamination might ... pipetting DNA/RNA solutions, infectious materials, ... applications requiring absolute sterility, they ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
Medicine Products: